[go: up one dir, main page]

KR930007925A - 탁솔의 수용성 유도체 - Google Patents

탁솔의 수용성 유도체 Download PDF

Info

Publication number
KR930007925A
KR930007925A KR1019920017573A KR920017573A KR930007925A KR 930007925 A KR930007925 A KR 930007925A KR 1019920017573 A KR1019920017573 A KR 1019920017573A KR 920017573 A KR920017573 A KR 920017573A KR 930007925 A KR930007925 A KR 930007925A
Authority
KR
South Korea
Prior art keywords
taxol
salt
taxolsodium
taxols
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019920017573A
Other languages
English (en)
Inventor
지.아이.킹스톤 데이비드
쟈오 지-양
Original Assignee
디오도르 콘
버지니아 테크 인텔렉츄얼 프러퍼티즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디오도르 콘, 버지니아 테크 인텔렉츄얼 프러퍼티즈 인코포레이티드 filed Critical 디오도르 콘
Publication of KR930007925A publication Critical patent/KR930007925A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

술폰화한 2'-아크로일 탁솔과 술폰화한 2′-0-아실란 탁솔 유도체는 생체활성은 유지하면서 수용성과 안정성이 증가하도록 합성된다. 특히 2′-〔(3-술포-1-옥소프로필)옥시〕탁솔소듐염은 탁솔을 아크릴산과 반응시키고, 2′-아크릴로일탁솔을 바이설파이트와 마이클 반응시킴으로써 얻어진다. 2′-{〔4-((2-슬포에틸)아미노)1.4-디옥소부틸〕옥시)탁솔소듐염과 2′-{〔4-((2-슬포에틸)아미노)1.4-디옥소부틸〕옥시)탁솔소듐염이 2′-숙시닐탁솔을 타우린의 테트라부틸 암모니움염과 3-아미노프로필술폰산과 각각 반응시키고, 후에 암모니움을 소둠으로 교환함으로써 얻어진다. 개선된 수용성을 갖는 2′-0-아실란 탁솔의 글리콜 유도체는 글리콜을 2′-0-아실란 탁솔과 반응시킴으로써 얻어진다.

Description

탁솔의 수용성 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1 도는 탁솔의 구조와 대응하는 탁솔 구조의 부분에 따라 표시된 피크를 갖는 탁솔의 NMR 스펙트럼이다.
제 2 도는 2′-0-신나모일탁솔(2′-신나모일탁솔)의 NMR 스펙트럼이다.
제 3 도는 2′-2-크로토닐탁솔(2′-크로토닐탁솔)의 NMR 스펙트럼이다.

Claims (2)

  1. 다음의 일반식을 갖는 탁솔 유도체 :
    상기식에서 X.Y 및 Z는 H, 알킬, 아릴로 이루어진 군에서 선택된다.(단, Y나 Z의 어느 하나가 H 인 경우, 나머지 하나는 X와 같을수 없다.)
  2. 다음의 일반식을 갖는 탁솔의 수용성 유체.
    상기식에서, X,Y,Z 및 W는 H, 알킬과 아릴로 이루어진 군에서 선택되어지고, M은 H, 알칼리 금속과 암모니오기로 이루어진 군에서 선택되어진다.(단, W나 X의 어느 하나가 H이고, Y나 Z의 어느 하나가 H인 경우, 각각의 나머지 하나는 서로 같지 않다.)
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920017573A 1991-10-15 1992-09-26 탁솔의 수용성 유도체 Ceased KR930007925A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/774,107 1991-10-15
US07/774,107 US5278324A (en) 1990-08-28 1991-10-15 Water soluble derivatives of taxol

Publications (1)

Publication Number Publication Date
KR930007925A true KR930007925A (ko) 1993-05-20

Family

ID=25100263

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920017573A Ceased KR930007925A (ko) 1991-10-15 1992-09-26 탁솔의 수용성 유도체

Country Status (13)

Country Link
US (1) US5278324A (ko)
EP (1) EP0537905B1 (ko)
KR (1) KR930007925A (ko)
AT (1) ATE135002T1 (ko)
CA (1) CA2080393A1 (ko)
CZ (1) CZ312292A3 (ko)
DE (1) DE69208802T2 (ko)
DK (1) DK0537905T3 (ko)
ES (1) ES2086669T3 (ko)
FI (1) FI924678L (ko)
GR (1) GR3020109T3 (ko)
NZ (1) NZ244754A (ko)
PL (2) PL296256A1 (ko)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5973160A (en) 1992-12-23 1999-10-26 Poss; Michael A. Methods for the preparation of novel sidechain-bearing taxanes
US5646176A (en) * 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
TW467896B (en) 1993-03-19 2001-12-11 Bristol Myers Squibb Co Novel β-lactams, methods for the preparation of taxanes and sidechain-bearing taxanes
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
DK1159974T3 (da) 1993-07-19 2007-11-26 Angiotech Pharm Inc Antiangiogene sammensætninger indeholdende taxol og en ikke-bionedbrydelig bærer og deres anvendelse
US6005120A (en) 1993-07-20 1999-12-21 Florida State University Tricyclic and tetracyclic taxanes
CA2174350A1 (en) * 1993-10-20 1995-04-27 Richard B. Greenwald 2'- and/or 7- substituted taxoids
CA2180156C (en) * 1994-01-11 2007-02-20 K. C. Nicolaou Self-assembled taxo-diperpenoid nanostructures
GB9405400D0 (en) * 1994-03-18 1994-05-04 Erba Carlo Spa Taxane derivatives
US5801191A (en) * 1995-06-01 1998-09-01 Biophysica Foundation Taxoids
AU716005B2 (en) * 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
CA2231750C (en) * 1995-09-12 2006-07-11 The Liposome Company, Inc. Hydrolysis-promoting taxane hydrophobic derivatives
US6107332A (en) 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
US6051600A (en) * 1995-09-12 2000-04-18 Mayhew; Eric Liposomal hydrolysis-promoting hydrophobic taxane derivatives
EP1229030B1 (en) * 1995-09-12 2005-11-09 Zeneus Pharma Limited Hydrolysis-promoting taxane hydrophobic derivates
US5840748A (en) * 1995-10-02 1998-11-24 Xechem International, Inc. Dihalocephalomannine and methods of use therefor
US5807888A (en) * 1995-12-13 1998-09-15 Xechem International, Inc. Preparation of brominated paclitaxel analogues and their use as effective antitumor agents
US5654448A (en) * 1995-10-02 1997-08-05 Xechem International, Inc. Isolation and purification of paclitaxel from organic matter containing paclitaxel, cephalomannine and other related taxanes
US5854278A (en) * 1995-12-13 1998-12-29 Xechem International, Inc. Preparation of chlorinated paclitaxel analogues and use thereof as antitumor agents
US6177456B1 (en) 1995-10-02 2001-01-23 Xechem International, Inc. Monohalocephalomannines having anticancer and antileukemic activity and method of preparation therefor
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
EP1616563A3 (en) * 1996-05-24 2006-01-25 Angiotech Pharmaceuticals, Inc. Perivascular administration of anti-angiogenic factors for treating or preventing vascular diseases
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
GB9705903D0 (en) 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
US20040234472A1 (en) 2001-04-20 2004-11-25 Jackson John K. Micellar drug delivery systems for hydrophobic drugs
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
CZ2003837A3 (cs) * 2000-09-22 2004-12-15 Bristol-Myers Squibb Company Způsob pro snížení toxicity při kombinovaných chemoterapiích
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
CA2440935A1 (en) * 2001-03-13 2002-09-19 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
ES2387562T3 (es) * 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
EP1427407A4 (en) 2001-03-23 2005-05-11 Luitpold Pharm Inc FAT AMIN DRUG CONJUGATES
JP4451660B2 (ja) 2001-11-30 2010-04-14 ブリストル−マイヤーズ スクイブ カンパニー パクリタキセル溶媒化合物
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
AU2003225495B2 (en) * 2002-04-05 2009-01-15 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation HIF-1alpha expression
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7713738B2 (en) * 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
US20070010702A1 (en) * 2003-04-08 2007-01-11 Xingwu Wang Medical device with low magnetic susceptibility
US20040254419A1 (en) * 2003-04-08 2004-12-16 Xingwu Wang Therapeutic assembly
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
CN100569945C (zh) 2003-12-23 2009-12-16 桑塔里斯制药公司 用于调节bcl-2的寡聚化合物
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
EA014097B1 (ru) * 2004-11-09 2010-08-30 Сантарис Фарма А/С ОЛИГОНУКЛЕОТИДЫ ЗАМКНУТОЙ НУКЛЕИНОВОЙ КИСЛОТЫ (LNA) ДЛЯ МОДУЛИРОВАНИЯ ЭКСПРЕССИИ HIF-1a И ИХ ПРИМЕНЕНИЕ
US20060154888A1 (en) * 2004-11-09 2006-07-13 Santaris Pharma A/S LNA oligonucleotides and the treatment of cancer
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
CA2597647A1 (en) 2005-02-11 2007-08-02 University Of Southern California Method of expressing proteins with disulfide bridges
US20070073385A1 (en) * 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
US20070196423A1 (en) * 2005-11-21 2007-08-23 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
EP1832577A1 (en) * 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California COMBINATION THERAPY FOR CANCER TREATMENT
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
WO2008005284A2 (en) 2006-06-30 2008-01-10 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8586625B2 (en) * 2008-01-16 2013-11-19 Anwar Rayan Derivatives of taxol and closely related compounds
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
US8642063B2 (en) * 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
AR099812A1 (es) 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
JP6877049B2 (ja) 2015-09-25 2021-05-26 ゼットワイ セラピューティクス インク．Ｚｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 多糖類−ビタミン共役体を含む粒状物に基づく薬物製剤
CN109562169A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
BR112018075649A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
CN116284404A (zh) 2016-06-08 2023-06-23 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
AU2017277916A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol

Also Published As

Publication number Publication date
FI924678L (fi) 1993-04-16
FI924678A0 (fi) 1992-10-15
CA2080393A1 (en) 1993-04-16
EP0537905A1 (en) 1993-04-21
PL296256A1 (en) 1993-10-18
CZ312292A3 (en) 1993-05-12
GR3020109T3 (en) 1996-08-31
DE69208802D1 (de) 1996-04-11
EP0537905B1 (en) 1996-03-06
NZ244754A (en) 1995-03-28
ATE135002T1 (de) 1996-03-15
DK0537905T3 (da) 1996-07-22
DE69208802T2 (de) 1996-10-02
ES2086669T3 (es) 1996-07-01
PL299303A1 (en) 1994-01-10
US5278324A (en) 1994-01-11

Similar Documents

Publication Publication Date Title
KR930007925A (ko) 탁솔의 수용성 유도체
RU92004362A (ru) Производные таксола и водорастворимые производные таксола
CA2049160A1 (en) Water soluble derivatives of taxol
TW581790B (en) Aqueous composition of a fluorescent whitener having excellent dyeing property
FI792849A (fi) Immunomodulatorer och antivirala aemnen
CA1141146A (en) Oil recovery by fluorochemical surfactant waterflooding
ATE152444T1 (de) N,n-disubstituierte amidsäuren, ihre ammoniumsalze sowie verwendung als emulgator
EP0312352A3 (en) Cyclodextrin derivatives and processes for preparing same
IE41052L (en) Use of an amine salt of p-alkylbenzenesulphonic acid in crop¹protection
KR860008144A (ko) 1,3- 디알킬 -2- 이미다졸리디논의 제조방법
KR900006355A (ko) 신규 페로센 유도체, 그것을 함유한 계면활성제 및 유기박막의 제조방법
KR840007578A (ko) 치환된 니트로 및 시아노구아니딘류의 제조방법
KR960014092A (ko) 이미노카르본산염 수용액 조성물 및 이미노카르본산염의 취급방법
KR970707086A (ko) 제이철 이온을 첨가하여 아연 및 망간 메티오닌 착염의 용해도를 향상시키는 방법(enhanced solubilization of zinc and manganese methionine complex salts byaddition of ferric ion)
US4012441A (en) Sulphonic derivatives having the structure of polyoxapolyfluoroalkanes
SU461493A3 (ru) Способ получени замещенной бензолсульфонилмочевины
US4310683A (en) Sulfosuccinate diesters
GB1350757A (en) Optical brightening agents
JPS562951A (en) Preparation of 2-cyanophenol derivative
KR920000371A (ko) 분체의 고결 방지방법
JPS57102957A (en) Dye-dissolving aid
KR940014504A (ko) 폴리에테르에스테르 블록공중합체의 제조방법
CA1068295A (en) Sulfosuccinate diesters
JPS5461185A (en) Nucleic acid base derivatives
KR830002718A (ko) 피라졸 유도체의 제조법

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920926

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19921113

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19920926

Comment text: Patent Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19950921

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19960321

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19950921

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Appeal kind category: Appeal against decision to decline refusal

Decision date: 19970331

Appeal identifier: 1996201000964

Request date: 19960503